IO Biotech Appoints Kathleen Sereda Glaub as Member of Board of Directors

IO Biotech Appoints Kathleen Sereda Glaub as Member of Board of Directors

COPENHAGEN, Denmark, June 11, 2018 /PRNewswire/ — IO Biotech, a clinical-stage biopharmaceutical company developing novel, immune modulating anti-cancer therapies, based on its proprietary T-win technology, today announced the appointment of Kathleen Sereda Glaub, MBA, as member of the Board of Directors. Ms. Glaub brings